Ocular surface @entity5 ( @entity957 ) of the socket: management of extensive XXXX with interferon.

@entity1 @entity390 @entity146 @entity5 @entity957 @entity1200 @entity4020 @entity484
PURPOSE: To describe the clinical features and management of extensive ocular surface @entity5 (OSSN) ( @entity957 ) of the socket. METHODS: Retrospective interventional case series. Interferon a 2b ( @entity4020 ) eye drops (1 million units/cc) 4 times daily and @entity4020 sublesional injection (5 million units/0.5cc to 8 million units/0.8 cc) were delivered for @entity5 control. @entity1 were 3 @entity1 with ocular prosthesis who developed extensive socket OSSN. Tumor control was graded as complete regression, partial regression, or no regression. RESULTS: OSSN was detected in the socket at age 60, 43, and 20 years in @entity1 who had worn ophthalmic prostheses for 54, 26, and 13 years, respectively. The @entity1 had chronic discharge and @entity146 (n = 3) managed with intermittent topical corticosteroids (n = 2). There were no predisposing factors of cigarette exposure, radiation exposure, @entity484 , @entity1200 , or organ transplantation. The prosthesis fit well with nonirritative edges. At presentation, OSSN was subtle (n = 3), vascular (n = 3), and multifocal (n = 3), with largest lesions or confluence of lesions measuring 20, 25, and 20 mm, respectively. The @entity5 involved the tarsal (n = 3), bulbar (n = 2), and forniceal (n = 2) surfaces. All @entity1 were treated with topical and injection @entity4020 , with complete regression achieved in 2 cases (at 1 months and 20 months) and partial regression in one case (at 9 months). All @entity1 continue on chronic maintenance @entity4020 topically. There were no recurrences, and @entity4020 injection side effects of @entity390 and chills were minor, lasting 1 day. No @entity1 required surgical removal of @entity5 from the socket and no @entity1 required exenteration. CONCLUSIONS: @entity1 wearing ophthalmic prosthesis over a socket should be monitored for the development of OSSN. Combined topical and injection @entity4020 could represent a potentially effective therapy for this condition.
